Cure My Disease

Don't miss your cure!

 Log in / Sign up

Robot aims to bust clots in the eye to save sight

NCT ID NCT07820761

Disease control Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Retinal vein occlusion happens when a clot blocks a vein in the eye, leading to vision loss. Current treatments manage the fluid buildup but do not remove the clot. This trial tests whether a robot can safely guide a tiny needle into the blocked vein to inject tPA, a clot-dissolving drug, directly at the site. Forty adults with a recent retinal vein occlusion join the study; half receive standard care and half receive standard care plus the robot-assisted injection, and researchers track safety and vision changes over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tissue plasminogen activator (tPA) delivered by robot-assisted retinal vein cannulation
What this could lead to
If it works, this could offer a way to dissolve the clot causing retinal vein occlusion and potentially restore blood flow before vision is permanently lost.
What could go wrong
The retinal veins are extremely small, so even with robotic help the injection may miss, fail to dissolve the clot, or cause bleeding or other damage. The trial is small and early, and it may not show a clear benefit over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant is wiling and able to give informed consent for participation in the trial * Male or Female aged 18 years or above * Recently diagnosed with central RVO (\<4 weeks) * In the Investigator's opinion, the patient is able and willing to comply with all trial requirements and is deemed fit for treatment. * ETDRS BCVA letter score of 70 or less or Snellen equivalent (\< 6/12) in the study eye at Screening Visit 1 Exclusion Criteria: * Participants with comorbidities contraindicating vitreoretinal surgery (e.g. excessive tremor) as determined by the investigator. * Participants with ocular comorbidities contraindicating the use of steroid implants (e.g. glaucoma) or anti-VEGFs as determined by the investigator. * Participants who are participating in another research trial involving an investigational product or surgical intervention. * Participants with known allergy to Fluorescein * Participants with contraindications for the use of tPA (Alteplase, Boehringer Ingelheim, Germany) or currently receiving or starting medications that have a known interaction with tPA, as identified in the SmPC, which may alter its efficacy or safety profile of tPA.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Central retinal vein occlusion are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

central retinal vein occlusion retinal vein occlusion

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Retinal vein occlusion (RVO)

Contacts and locations

Locations

  • Eye Research Group Oxford, Oxford Eye Hospital, LG1, West Wing of the John Radcliffe Hospital

    Oxford, Oxfordshire, OX3 9DU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.